Tag: Daiichi Sankyo AstraZeneca Datroway

Home / Daiichi Sankyo AstraZeneca Datroway

Categories

Datopotamab deruxtecan-dlnk is approved by the USFDA for EGFR-mutated non-small cell lung cancer

On June 23, 2025, the Food and Drug Administration conferred accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adults with locally advanced or metastatic epiderm...
daiichi-sankyo-astrazeneca-datroway

Scan the code